Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) have received a consensus rating of “Hold” from the twenty-four ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $46.65.
Several analysts have weighed in on the company. Canaccord Genuity set a $34.00 price target on Pacira Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, June 29th. Wedbush reiterated an “outperform” rating and set a $80.00 price target (down previously from $85.00) on shares of Pacira Pharmaceuticals in a research note on Monday, August 6th. ValuEngine upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 3rd. BMO Capital Markets boosted their price target on Pacira Pharmaceuticals to $40.00 and gave the company a “neutral” rating in a research note on Thursday, August 2nd. They noted that the move was a valuation call. Finally, Royal Bank of Canada set a $50.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 2nd.
In related news, CEO David M. Stack sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $33.79, for a total value of $844,750.00. Following the completion of the transaction, the chief executive officer now owns 115,446 shares of the company’s stock, valued at approximately $3,900,920.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kristen Marie Williams sold 2,040 shares of the company’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $33.02, for a total value of $67,360.80. Following the completion of the transaction, the chief accounting officer now directly owns 19,272 shares of the company’s stock, valued at approximately $636,361.44. The disclosure for this sale can be found here. In the last three months, insiders sold 49,093 shares of company stock valued at $1,700,983. Insiders own 5.90% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. US Bancorp DE grew its position in shares of Pacira Pharmaceuticals by 53.8% during the 1st quarter. US Bancorp DE now owns 4,292 shares of the company’s stock worth $134,000 after buying an additional 1,501 shares during the period. Fisher Asset Management LLC grew its position in Pacira Pharmaceuticals by 29.6% in the 1st quarter. Fisher Asset Management LLC now owns 6,848 shares of the company’s stock valued at $213,000 after purchasing an additional 1,566 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in Pacira Pharmaceuticals in the 2nd quarter valued at $219,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Pacira Pharmaceuticals in the 2nd quarter valued at $312,000. Finally, Wedbush Securities Inc. acquired a new stake in Pacira Pharmaceuticals in the 1st quarter valued at $314,000.
Pacira Pharmaceuticals traded up $0.73, hitting $45.95, on Tuesday, MarketBeat.com reports. 426,519 shares of the company’s stock were exchanged, compared to its average volume of 646,402. Pacira Pharmaceuticals has a 12-month low of $26.95 and a 12-month high of $47.55. The company has a debt-to-equity ratio of 0.98, a current ratio of 8.58 and a quick ratio of 7.79. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -79.22 and a beta of 1.83.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, August 2nd. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.37. The business had revenue of $84.10 million for the quarter, compared to the consensus estimate of $77.53 million. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The company’s quarterly revenue was up 18.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.11) EPS. equities research analysts anticipate that Pacira Pharmaceuticals will post -0.51 earnings per share for the current year.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Recommended Story: Diversification in Your Portfolio
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.